Read More

Lexaria Bioscience Corp. Announces That The Co’s Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND")

LEXX

Read More

Biomea Fusion To Present Long-Term Follow-Up Data From Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes And Results From Ex-Vivo Human Islet Experiments At The World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7th at 6:30pm and an oral

BMEA